Canopy Growth (CGC) Liabilities and Shareholders Equity (2017 - 2026)
Canopy Growth (CGC) reported Liabilities and Shareholders Equity of $815.8 million for Q1 2026, up 27.55% on a YoY basis from $639.6 million in Q1 2025, and up 2.84% sequentially from $793.2 million in Q4 2025.
Canopy Growth (CGC) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends
Canopy Growth (CGC) has 10 years of Liabilities and Shareholders Equity data on file, last reported at $815.8 million in Q1 2026.
- For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 27.55% year-over-year to $815.8 million; the trailing twelve-month figure through Mar 2026 stood at $3.0 billion (down 8.36% YoY), and the FY2026 full-year result was $815.8 million, up 27.55% from the prior year.
- Liabilities and Shareholders Equity rose to $815.8 million in Q1 2026, from $793.2 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $4.4 billion in Q1 2022 to a low of $639.6 million in Q1 2025.
- A 5-year average of $1.5 billion and a median of $965.0 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity sank 59.22% in 2023 and rose 27.55% in 2026, its largest moves.
- Tracing CGC's Liabilities and Shareholders Equity over 5 years: stood at $2.2 billion in 2022, then plunged by 53.88% to $998.8 million in 2023, then declined by 16.56% to $833.4 million in 2024, then dropped by 4.82% to $793.2 million in 2025, then rose by 2.84% to $815.8 million in 2026.
- Business Quant data shows CGC's Liabilities and Shareholders Equity at $815.8 million in Q1 2026, $793.2 million in Q4 2025, and $777.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 43.40 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 40.04 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 15.15 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 98.91 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 6.71 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 69.30 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 36.83 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 4.91 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.22 Bn |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - | 815.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 815.79 Mn |
| Dec 31, 2025 | 793.24 Mn |
| Sep 30, 2025 | 777.38 Mn |
| Jun 30, 2025 | 652.91 Mn |
| Mar 31, 2025 | 639.56 Mn |
| Dec 31, 2024 | 833.41 Mn |
| Sep 30, 2024 | 903.38 Mn |
| Jun 30, 2024 | 940.41 Mn |
| Mar 31, 2024 | 964.99 Mn |
| Dec 31, 2023 | 998.79 Mn |
| Sep 30, 2023 | 1.24 Bn |
| Jun 30, 2023 | 1.63 Bn |
| Mar 31, 2023 | 1.80 Bn |
| Dec 31, 2022 | 2.17 Bn |
| Sep 30, 2022 | 2.55 Bn |
| Jun 30, 2022 | 2.75 Bn |
| Mar 31, 2022 | 4.43 Bn |
| Dec 31, 2021 | 5.01 Bn |
| Sep 30, 2021 | 5.16 Bn |
| Jun 30, 2021 | 5.67 Bn |